Psychiatric Adverse Events in Randomized, Double-Blind, Placebo-Controlled Clinical Trials of Varenicline: A Pooled Analysis
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Background Varenicline (Chantix), Champix) has shown efficacy and tolerability as an aid to smoking cessation. In postmarketing surveillance, neuropsychiatric symptoms have appeared; however, their incidence and causal relationship to varenicline is not known. Objective We assessed the incidence and relative risk (RR) of psychiatric disorders in ten randomized, double-blind, placebo-controlled trials of varenicline for smoking cessation. Methods All smoking cessation phase II, III and IV randomized controlled clinical trials of varenicline versus placebo completed as of 31 December 2008, on file with the manufacturer (Pfizer, Inc.), were included. All studies have been published. All 3091 participants who received at least one dose of varenicline and all 2005 participants who received placebo were included in this analysis. These were men and women smoking > or =10 cigarettes/day, aged 18-75 years and without current psychiatric disease who received varenicline or placebo for 6 (one study), 12 (eight studies) or 52 (one study) weeks. Adverse events were recorded at each study visit and classified according to standard Medical Dictionary for Regulatory Activities (MedDRA) terms (version 11.0). Results The incidence of psychiatric disorders other than solely sleep disorders and disturbances was 10.7% in subjects treated with varenicline and 9.7% in subjects treated with placebo, with an RR of 1.02 (95% CI 0.86, 1.22). The RRs (95% CI) versus placebo of psychiatric adverse event…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The authors reported no cases of suicidal ideation or behavior in varenicline-treated subjects in the 10 placebo-controlled studies analyzed.”
From Are smoking cessation treatments associated with suicidality risk? An overview (2016) · cites this paper as [45]
In the citing paper
“However, among three trials that were excluded from the analysis because of their open-label design, two cases of suicidal ideation and one completed suicide were reported in patients who had been treated with varenicline.”
From Are smoking cessation treatments associated with suicidality risk? An overview (2016) · cites this paper as [45]
In the citing paper
“Additionally, Tonstad et al.45 in a pooled analysis examined the incidence of psychiatric adverse events in 10 completed RCTs of varenicline and that the incidence of psychiatric disorders other than sleep disorders and disturbances was 10.7% in subjects treated with varenicline and 9.7% in subjects treated with placebo, with an RR of 1.02 (95% CI: 0.86, 1.22).”
From Are smoking cessation treatments associated with suicidality risk? An overview (2016) · cites this paper as [45]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738
Nicotine replacement therapy for smoking cessation
Stead, L. F., Perera, R., Bullen, C., Mant, D., Hartmann-Boyce, J., Cahill, K., & Lancaster, T. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub4 · Cited by 2,464
Antidepressants for smoking cessation
Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub5 · Cited by 1,352
The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality: A Randomized Clinical Trial
Anthonisen, N. R., Skeans, M. A., Wise, R. A., Manfreda, J., Kanner, R. E., Connett, J. E., & for the Lung Health Study Research Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-4-200502150-00005 · Cited by 1,237
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930
Nicotine receptor partial agonists for smoking cessation
Hey, K., Lancaster, T., & Bala, M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103 · Cited by 861
Steyerberg, E. W., Eijkemans, M. J. C., Harrell, F. E., & Habbema, J. D. F. (2000) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(20000430)19:8<1081::aid-sim406>3.0.co;2-a · Cited by 802
Research works printed but not linked: 6
- Cahill, 2008, Cochrane Database Syst Rev, &NA;, CD006103
- Hughes, 2007, Cochrane Database Syst Rev, &NA;, CD000031
- Stead, 2008, Cochrane Database Syst Rev, &NA;, CD000146
- Kutscher, 2009 May, S D Med, 62, 193
- Agresti, 2000 Apr 30, Stat Med, 19, 1115, 10.1002/(SICI)1097-0258(20000430)19:8<1115::AID-SIM408>3.0.CO;2-X · DOI · Paper page
- Gunnell, 2009, BMJ, 339, 1072
Cited by
Pharmacological interventions for smoking cessation: an overview and network meta-analysis
Cahill, K., Stevens, S., Perera, R., & Lancaster, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009329.pub2 · Cited by 1,243
Anthenelli, R. M., Benowitz, N. L., West, R., St Aubin, L., McRae, T., Lawrence, D., Ascher, J., Russ, C., Krishen, A., & Evins, A. E. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30272-0 · Cited by 1,177
Self-citationNicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub7 · Cited by 433
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“There have been reports of possible serious adverse events, including depressed mood, agitation and suicidal thoughts, but their relationship to varenicline has not been substantiated (Gunnell et al., 2009; Tonstad et al., 2010) (III).”
Background
Metadata
- Authors
- Tonstad, S., Davies, S., Flammer, M., Russ, C., & Hughes, J.
- Affiliations
- Oslo University Hospital (NO)
- Pfizer (United States) (US)
- University of Vermont (US)
- Corresponding author
- Tonstad, Serena
- Venue
- Drug Safety
- Published
- 2010-04
- Volume
- 33
- Issue
- 4
- Pages
- 289-301
- ISSN
- 0114-5916 (ISSN-L)
- OpenAlex
- W2055445378
- Cited by
- 142
- References
- 50
- Citations by year
- 2025: 2 · 2022: 4 · 2021: 8 · 2020: 3 · 2019: 3 · 2018: 5 · 2017: 3 · 2016: 12 · 2015: 18 · 2014: 8 · 2013: 18 · 2012: 25
- FWCI
- 16.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Sanofi
- University of Vermont
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- varenicline, psychiatric adverse events, smoking cessation, neuropsychiatric symptoms, anxiety disorders, mood disorders, sleep disorders, relative risk, adverse event incidence, suicidal ideation, nicotine receptor partial agonist, antidepressant side effects, antidepressant withdrawal symptoms, antidepressant-induced mania, antidepressant-induced hypomania
- MeSH terms
- Varenicline, Adolescent, Adult, Aged, Mental Disorders, Benzazepines, Double-Blind Method, Female, Humans, Male, Middle Aged, Placebos, Quinoxalines, Risk, Sleep Wake Disorders, Incidence, Randomized Controlled Trials as Topic, Smoking Cessation, Nicotinic Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Psychiatric Adverse Events in Randomized, Double-Blind, Placebo-Controlled Clinical Trials of Varenicline: A Pooled Analysis. https://app.cochat.ai/papers/10.2165/11319180-000000000-00000
- The paper
- Tonstad, S., Davies, S., Flammer, M., Russ, C., & Hughes, J. (2010). Psychiatric Adverse Events in Randomized, Double-Blind, Placebo-Controlled Clinical Trials of Varenicline: A Pooled Analysis. Drug Safety. https://doi.org/10.2165/11319180-000000000-00000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.